Please login to the form below

Not currently logged in
Email:
Password:

BioAlliance announces managerial changes

Dr Gilles Avenard resigns as board member and deputy CEO in charge of R&D, while Dr Pierre Attali becomes CEO

BioAlliance Pharma, a company dedicated to the supportive care and treatment of cancer patients, has announced changes to its management structure.

Dr Gilles Avenard has resigned as board member and deputy CEO in charge of R&D, while Dr Pierre Attali, who has been serving BioAlliance Pharma as chief medical officer for several years, has been appointed as the company's CEO.

Dominique Costantini, CEO of BioAlliance Pharma commented: "I am delighted by Pierre Attali's appointment. His international experience in drug development, notably at Synthelabo, and his hospital practice are major assets for both the company and its commercial partners when preparing the next launches of BioAlliance's products."

4th August 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics